Stable MTHF-Ca Formulations for MTHFR Polymorphism Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Individuals with MTHFR polymorphisms face challenges in converting folic acid to its active form, 5-methyltetrahydrofolate, due to impaired methylation pathways, leading to deficiencies that contribute to various chronic degenerative diseases, and existing treatments using inactive forms of folic acid and cyanocobalamin are ineffective in such cases.
Innovation Solution
Development of stable formulations of methyltetrahydrofolate calcium (MTHF-Ca) that maintain potency for up to 40 days when stored under refrigeration, involving specific methods of preparation including the addition of sodium metabisulfite, sterile water, preservatives, and pH adjustment to create compositions suitable for various administration routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional oral supplementation with inactive forms of folic acid and cyanocobalamin is used, then the treatment approach is simple and widely available, but the conversion to active forms is impaired in individuals with MTHFR mutations, rendering the treatment ineffective
Solution Approach 1:
The patent changes the chemical form of folic acid from inactive synthetic folic acid to active 5-methyltetrahydrofolate (MTHF), and similarly converts cyanocobalamin to active methylcobalamin. This parameter change in molecular structure ensures the supplements are immediately bioactive and do not require functional conversion by impaired enzymes in individuals with MTHFR mutations, thereby resolving the contradiction between treatment simplicity and effectiveness.
2Stability of the object's composition
If stable formulations of MTHF-Ca are developed with multiple additives and preservation steps, then the stability and potency retention is improved, but the manufacturing process complexity increases
Solution Approach 1:
The patent incorporates multiple protective agents (sodium metabisulfite as antioxidant, preservatives, pH adjusters) into the formulation during manufacturing to preemptively prevent degradation. The formulation is designed with built-in stability mechanisms that activate upon preparation, allowing the product to maintain potency for up to 40 days when stored under refrigeration, thus resolving the contradiction between stability and manufacturing ease by preparing the protective system in advance during production.
3Reliability
If the body attempts to convert folic acid to active MTHF through multiple metabolic steps, then the natural metabolic pathway is utilized, but the conversion process is impaired in individuals with methylation pathway mutations
Solution Approach 1:
The patent extracts the essential active component (5-methyltetrahydrofolate) from the complex folic acid conversion pathway and delivers it directly in its bioactive form. By taking out the final active product and bypassing the entire multi-step metabolic conversion process, the invention eliminates the reliability issue of impaired conversion in MTHFR mutation carriers while avoiding the complexity of ensuring proper metabolic function.
4Ease of operation
If oral supplementation is used to deliver folic acid, then the administration route is simple and non-invasive, but the absorption and conversion efficiency is greatly reduced in individuals with compromised gut health
Solution Approach 1:
The patent changes the chemical parameter of the supplement from inactive folic acid requiring absorption and conversion to active MTHF that is immediately bioavailable. This parameter change ensures that even with compromised gut health, the active form can be directly absorbed and utilized without relying on intact metabolic conversion pathways, thus resolving the contradiction between administration simplicity and absorption reliability.
Data Source
AI summary
Provided herein are methods for preparing stable solutions containing 5-methyltetrahydrofolate (MTHF). Also provided herein are stable compositions containing calcium 5-methyltetrahydrofolate (MTHF-Ca).